AMCP has released Version 4.1 of the AMCP Format for Formulary Submissions, which includes two new dossier types for biopharmaceutical manufacturers to share evidence on unapproved products and new indications that are under review by the U.S. Food and Drug Administration (FDA).
AMCP last week gathered a group of diverse health care stakeholders to discuss the challenges and opportunities of ensuring patient access to a category of emerging therapies known as “digital therapeutics,” which have the potential to treat a wide range of diseases and medical conditions.
This JMCP article describes how discoveries made through a validation process improved the accuracy and transparency of a previously published budget impact analysis model that overestimated utilization following a formulary change.
This JMCP article describes how discoveries made through a validation process improved the accuracy and transparency of a previously published budget impact analysis model that overestimated utilization following a formulary change.
Partnership Forum: Participants examined how to improve decision making for prior authorization and step therapy based on current market dynamics and considerations to ensure patients receive the most appropriate medications.